The NAD+ reading shelf

Vinten’s review narrows the human claim

For the front of the shelf, I’d choose Vinten and colleagues, 2025. Its subject is human NAD+ precursor supplementation, and it is particularly useful on the distance between blood changes and clinical efficacy. For the underlying cellular machinery, Covarrubias and colleagues, 2021 and Ying’s review of NAD-related cellular functions supply the larger biochemical setting.

The human findings

Conze: NR and whole-blood NAD+ is the dose-response paper. Yi: NMN, blood NAD+ and walking distance asks a broader functional question. Yoshino: NMN and muscle insulin sensitivity belongs beside them, with its prediabetic, postmenopausal population kept in mind.

For the cardiovascular case, read Wang: NR tolerability in heart failure alongside Freeberg: systolic pressure and arterial stiffness. They do not measure the same outcome.

The experiments that unsettle the simple story

Camacho-Pereira: CD38 and aging mice gives the decline a mechanism. Zhang: NMN and pressure-overload heart failure in mice contains the striking survival result. Williams: vitamin B3 and glaucoma-prone mice concerns eyes rather than a general aging verdict.

Audrito: NAD+ synthesis as a melanoma vulnerability and Garrido and Djouder: NAD+ deficits, aging and cancer are the pair that prevents replenishment becoming a universal answer. Yoshino’s diabetes experiments in mice and Li’s SIRT3 review complete the animal and mechanistic portion of this list.